Breakthrough in Waldenstrom's Macroglobulinemia Treatment: Cellectar Biosciences Achieves Primary Endpoint in Pivotal Clinical Study.
Bioscience Company Achieves Promising…
Breakthrough in Waldenstrom's Macroglobulinemia Treatment: Cellectar Biosciences Achieves Primary Endpoint in Pivotal Clinical Study.